Skip to contentS
Skye Bioscience, Inc.
S
SKYESkye Bioscience, Inc. Released May 11, 2023, after the close
10-Q filed May 12, 2023, 42 days after period end · 0001516551-23-000041
Q1 2023 · 10-Q
Revenue—
Net Income-$5.17M-$5.17MN/M vs Q1 2022N/M vs Q4 2022 EPS Diluted
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
-$1.37-$1.37N/M vs Q1 2022no prior Q4 2022 on file Operating Income-$3,100,158N/M Operating Cash Flow-$4,060,923N/M Free Cash Flowderived-$4,062,783N/M Filing lag
ended Mar 31, 2023 · filed May 12, 2023 · 42 d after period end